Life Sciences Transformational R&D Investment Fund (TRIF) Pilot
The Life Sciences Transformational R&D Investment Fund Pilot offers capital grants to support large-scale R&D projects in the UK life sciences sector (eligible projects must exceed £100 million in total costs).
Read the official page on Find a grant ↗Start an application ↗ Get new grants like this
- Funder
- Department for Science, Innovation and Technology
- Where
- 🇬🇧 United Kingdom — England, Wales, Scotland, Northern Ireland, North East England, North West England, South East England, South West England, Midlands
- Status
- Open, rolling
- Opened
- 25 Sep 2025
- Funding
- £5m–£25m per award (£50m in total)
- Who can apply
- Small businesses
- Topics
- Health Science & research Innovation & technology
About this grant
The Life Sciences Transformational R&D Investment Fund Pilot is a newly established £50 million capital grant opportunity.
It aims to boost research and development (R&D) within the UK's Life Sciences sector by supporting large-scale investments focused on innovation and strengthening health resilience. The fund prioritises projects with the potential to generate economic benefits. This is a new fund that works alongside the separate Life Sciences Innovative Manufacturing Fund (LSIMF).
Projects with a total cost (including capital expenditure) of at least £100 million are eligible to apply.
The grant awarded is set at the minimum level necessary to ensure your project proceeds while adhering to UK subsidy regulations, typically ranging from 10-20% of total project costs. For instance, a project with a total cost of £100 million would generally receive a grant of £10-20 million.
Objectives
Objective 1: Health Resilience and Innovation
Health resilience is defined as the ability of the UK to withstand and recover from health emergencies, including pandemics, long-term healthcare challenges, and system shocks such as disruptions to supply chains. In this context, innovation refers to the development and implementation of new technologies, processes, and products that serve to improve health outcomes, enhance manufacturing capabilities, and accelerate access to clinical trials for UK patients.
Your R&D project should support or demonstrate how it will strengthen health resilience and foster innovation in the UK by achieving one or more of the following:
· Drive the creation of new or expansion of existing UK R&D capacity, supporting innovation in Life Sciences and ensuring the UK is better equipped to respond to emerging healthcare challenges. This could include areas such as: drug discovery and development; medical device design and feasibility; preclinical or clinical research; enhancing manufacturing processes and production efficiency.
· Enhance flexibility in R&D facilities, capabilities and technologies, enabling rapid redeployment or scaling during health emergencies. This could be through investment in areas such as: optimising or accelerating clinical research or product testing; deploying new AI or digital research approaches; testing or deploying innovative materials or technologies; advancing manufacturing.
By focusing on these impact areas, your project will help reinforce the UK's health resilience and drive forward innovation in Life Sciences, supporting both immediate and long-term national health and economic priorities.
Objective 2: Creating Economic Opportunity
To ensure the impact of R&D initiatives extends beyond healthcare improvements, projects should clearly demonstrate their contribution to the UK economy. This can be achieved through several key avenues:
· Substantial Contribution to Gross Value Added (GVA):
Projects are expected to deliver significant economic value by engaging in high-impact R&D activities that enhance the overall productivity and output of the UK economy.
· Creation of High-Wage, High-Skilled Jobs:
Efforts should focus on generating employment opportunities that require advanced skills and offer competitive wages. Special emphasis is placed on creating such opportunities across the UK, particularly in regions that have untapped potential or that already host established Life Sciences clusters.
· Generating R&D spillover benefits:
R&D investment often generate economic benefits by enabling knowledge transfer across firms, sectors and regions. These spillover effects enhance productivity, stimulate new business formation and strengthen the UK’s innovation ecosystem, particularly when linked to collaborative clusters and high-potential technologies.
Dates
The TRIF Pilot will run until 31 March 2030 or until all of the funding has been allocated; applications will run on a roling basis.
If your application is successful at Stage 1, independent panel interviews will take place monthly.
Eligibility
Your Company
To be considered eligible for the TRIF Pilot, your company must meet the following requirements:
Be a UK-registered and wholly private sector business.
Operate as a product developer, contract development and manufacturing organisation (CDMO), or generics manufacturer.
Provide two years of audited accounts for the applicant company or parent entity. If unavailable, you must demonstrate that the remaining project funding has been secured.
Show a track record of successfully developing or manufacturing medicines or medical devices, either in the UK or internationally.
Your Project
To be eligible for the fund, your R&D project must:
Have a total cost (including eligible capital and non-capital costs) of at least £100m.
Be located in the UK.
Be primarily a capital investment.
Be a single company investment (as opposed to forming a partnership between companies or other types of organisations)
Be dependent on the grant to proceed. Projects that would otherwise not occur, be delayed (by three years or more), scaled down, or relocated overseas without the grant may be eligible.
R&D Focus Areas
Applications are invited to support projects that are engaged in R&D activities within the following key areas:
· Human Medicines: This includes projects that focus on the development and innovation of pharmaceuticals, encompassing both active pharmaceutical ingredients (APIs) and finished drug products intended for human use.
· Medical Diagnostics: Projects aimed at advancing tools, systems, or methods for the identification and monitoring of diseases. This area covers the R&D of diagnostic technologies that support timely and accurate disease detection.
· MedTech Products: This covers the creation and enhancement of medical devices specifically related to human health. Eligible projects may involve the design, testing, or improvement of medical devices.
Ineligible Projects:
Projects relating to the following are not eligible for funding from the TRIF Pilot:
Veterinary medicines
Herbal medicines
Nutritional supplements or vitamins
Raw ingredients (e.g solvents, buffers and cleaning agents)
The production of single-use consumables that are not integrated into a larger product (e.g manufacturing syringes independently from diagnostic kits)
Secondary packaging for products or materials (e.g package inserts, labelling and boxes)
Applying for grants? Grants Pro e-mails you every morning with the new grants and opened forecasts that match your saved searches, and adds deadline reminders in your calendar, a private RSS feed and CSV export. Try it free for 7 days, then $9/month, cancel any time. See what Pro does →
Applying? Read how to write a winning grant proposal.
Contains public sector information licensed under the Open Government Licence v3.0 (Find a grant). Last checked 19 Nov 2026. Always read the official page before applying: it has the full conditions, documents and how to apply.